Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma (Q33369640)

26 July 2017

title

Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

7

Ruben Niesvizky

1 reference

26 July 2017

Alan D Dosik

1

1 reference

26 July 2017

Morton Coleman

2

1 reference

26 July 2017

Lale Kostakoglu

3

1 reference

26 July 2017

Richard R Furman

4

1 reference

26 July 2017

Jennifer M Fiore

5

1 reference

26 July 2017

Daniel Muss

6

1 reference

26 July 2017

Tsiporah Shore

8

1 reference

26 July 2017

Michael W Schuster

9

1 reference

26 July 2017

Patricia Stewart

10

1 reference

26 July 2017

Shankar Vallabhajosula

11

1 reference

26 July 2017

Stanley J Goldsmith

12

1 reference

26 July 2017

John P Leonard

13

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

26 July 2017

1 reference

26 July 2017

volume

106

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

616-622

1 reference

The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

The epidemiology of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

Treatment of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

Follicular lymphoma: prognostic factors for response and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

Radioimmunotherapy of non-Hodgkin lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

The radioisotope contributes significantly to the activity of radioimmunotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

Hydrops fetalis-associated congenital dyserythropoietic anemia treated with intrauterine transfusions and bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

131I-tositumomab therapy as initial treatment for follicular lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21606

7 January 2021

Identifiers

DOI

10.1002/CNCR.21606

1 reference

26 July 2017

1 reference